Celyad Oncology
(NASDAQ:CYAD)
$1.3535
0.0035[0.26%]
Last update: 2:42PM (Delayed 15-Minutes)
Get Real Time Here
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary

Celyad Oncology Stock (NASDAQ: CYAD) stock price, news, charts, stock research, profile.

Loading...
Day Range1.250 - 1.42052 Wk Range0 - 3.630Open / Close1.310 / -Float / Outstanding- / 22.594M
Vol / Avg.40.027K / 1.446MMkt Cap30.581MP/E-50d Avg. Price1.050
Div / Yield (Forward)- / -%Payout Ratio-Total Float-EPS-1.300
Globe Newswire - Jun 24, 2022, 1:05AM
InvestorsObserver - Jan 25, 2023, 10:45AM
InvestorsObserver - Jan 24, 2023, 9:09AM
InvestorsObserver - Jan 20, 2023, 5:42AM
InvestorsObserver - Jan 19, 2023, 5:54AM
Seeking Alpha - Jan 17, 2023, 12:51PM
InvestorsObserver - Sep 26, 2022, 6:48AM
Seeking Alpha - Aug 2, 2022, 8:39AM
Seeking Alpha - Jul 19, 2022, 8:30AM
TipRanks - Feb 28, 2022, 11:39AM
Sector: Health Care.Industry: Biotechnology
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Earnings

see more
FY 2022Est.ActualSurprise
EPS
(EXPECTED)2023-04-09
REV
H1 2022Est.ActualSurprise
EPS-0.660
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Celyad Oncology (CYAD) stock?

A

You can purchase shares of Celyad Oncology (NASDAQ: CYAD) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Celyad Oncology's (CYAD) competitors?

Q

What is the target price for Celyad Oncology (CYAD) stock?

A

The latest price target for Celyad Oncology (NASDAQ: CYAD) was reported by Wells Fargo on Tuesday, January 11, 2022. The analyst firm set a price target for 11.00 expecting CYAD to rise to within 12 months (a possible 712.71% upside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Celyad Oncology (CYAD)?

A

The stock price for Celyad Oncology (NASDAQ: CYAD) is $1.3535 last updated Today at February 1, 2023 at 7:42 PM UTC.

Q

Does Celyad Oncology (CYAD) pay a dividend?

A

There are no upcoming dividends for Celyad Oncology.

Q

When is Celyad Oncology (NASDAQ:CYAD) reporting earnings?

A

Celyad Oncology’s FY earnings are confirmed for Sunday, April 9, 2023.

Q

Is Celyad Oncology (CYAD) going to split?

A

There is no upcoming split for Celyad Oncology.

Q

What sector and industry does Celyad Oncology (CYAD) operate in?

A

Celyad Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.